NUWENasdaqElectromedical & Electrotherapeutic ApparatusUS GAAP · USD

Nuwellis, Inc.

Nuwellis, Inc. is a U.S.-based medical technology company focused on the Aquadex System, an ultrafiltration platform used to remove excess fluid from patients. Its business combines console systems, disposable blood filters and catheters, and related clinical support for hospitals and clinics, with sales centered in the United States and selected international markets.

Kysy yhtiöstä
Liikevaihto8,3milj. USD
−5,4 %v/v
Liikevoitto (EBIT)−11,1milj. USD
−1,1 %v/v
EBIT-marginaali−134,3%
−8,6 %-yks.v/v
Nettotulos−17,5milj. USD
−56,9 %v/v
Vapaa kassavirta−10,9milj. USD
−12,9 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−20−10010milj. USD2020: 7,4 milj. USD2020: EBIT −17 milj. USD20202021: 7,9 milj. USD2021: EBIT −20 milj. USD20212022: 8,5 milj. USD2022: EBIT −17 milj. USD20222023: 8,9 milj. USD2023: EBIT −18 milj. USD20232024: 8,7 milj. USD2024: EBIT −11 milj. USD20242025: 8,3 milj. USD2025: EBIT −11 milj. USD20258,3−11
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Nuwellis, Inc.

Liiketoiminta

Osuus liikevaihdosta
Aquadex console systems20 %

Capital equipment used to deliver ultrafiltration therapy in hospital settings.

Disposable circuits and blood sets60 %

Single-use blood filters and catheters used with Aquadex consoles.

Technical services and support10 %

Training, implementation, and clinical support provided to hospital customers.

International distributor sales5 %

Sales outside the U.S. through specialty distributors in selected markets.

Other product and development-related revenue5 %

Other device-related sales and commercial activity tied to the Aquadex platform.

Asiakkaat

Nuwellis sells primarily to hospitals, health systems, and academic medical centers that treat fluid overload in complex patients. Its core users include cardiac surgery, heart failure, critical care, and pediatric programs that need controlled fluid removal and clinical support around therapy delivery.

U.S. hospitals and health systems

Buy Aquadex consoles, disposables, and support for inpatient fluid management programs.

Academic medical centers

Use the system in advanced heart failure and critical care protocols where clinical evidence matters.

Cardiac surgery programs

Use ultrafiltration around post-cardiac surgery fluid management and recovery.

Pediatric hospitals

Adopt the pediatric-cleared system for children needing kidney replacement or fluid therapy.

International specialty distributors

Purchase products for resale to hospitals and clinics in their local markets.

Strategia

Nuwellis is prioritizing commercial investment in U.S. cardiac surgery, pediatric, and hospital-based outpatient opportunities where it sees the strongest clinical demand. It is also extending the Aquadex platform through software upgrades and product enhancements, while evaluating adjacent renal-monitoring technologies that could broaden its care platform.

Concentrate on the U.S. marketLyhyt aikaväli

The company believes U.S. demand offers the strongest near-term commercial opportunity and supportability.

Expand pediatric and cardiac surgery adoptionKeskipitkä aikaväli

These clinical settings can increase utilization of the Aquadex platform and deepen hospital relationships.

Improve product performance and user experienceKeskipitkä aikaväli

Device enhancements can support customer satisfaction, retention, and broader clinical use.

Broaden the platform beyond ultrafiltrationPitkä aikaväli

Adjacent monitoring technologies could extend the company’s role in cardiorenal care.

Maantiede

Nuwellis is centered in the United States, where it sells through a direct salesforce and has ten sales territories. It also serves selected foreign jurisdictions through independent specialty distributors, but the company has stated that its focus is the U.S. market and a small set of retained international markets.

Riskit

Nuwellis depends on a concentrated customer base, third-party manufacturing, and continued access to capital, so disruptions in any of these areas could materially affect operations. As a medical device company, it also faces regulatory, clinical adoption, reimbursement, and product-performance risks that can slow commercialization or limit utilization.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Capital funding risk1Nasdaq listing compliance2Customer concentration3Third-party manufacturing and supply chain4Clinical adoption and reimbursement5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Capital funding riskVaikutus: KriittinenTodennäköisyys: Korkea

    The company expects to need additional capital to support operations and strategic initiatives.

    Kohdistuu: Operating runway and growth investment

  2. Nasdaq listing complianceVaikutus: KorkeaTodennäköisyys: Korkea

    The stock has faced minimum stockholders' equity and bid-price compliance pressure.

    Kohdistuu: Potential delisting and trading restrictions

  3. Customer concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen

    A limited number of customers account for a large share of revenue, so loss or reduced ordering can materially hurt sales.

    Kohdistuu: Largest customer represented 13.7% of annual revenue

  4. Third-party manufacturing and supply chainVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company depends on external manufacturers and suppliers for commercial volumes and components.

    KohdistuuBackordersProduction delaysRationing
  5. Clinical adoption and reimbursementVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Hospitals must adopt ultrafiltration therapy and justify use versus competing treatments.

    KohdistuuHeart failureCritical carePediatric programs
Kysy Clarifolta: Nuwellis, Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition timing

Sales of consoles, disposables, and services are recognized when control transfers, which can shift revenue between periods.

Vaikutus: Quarterly comparability

Warrant valuation

Freestanding warrants may be classified as liabilities and remeasured at fair value.

Vaikutus: Non-cash earnings volatility

Long-lived asset impairment

The company must assess whether equipment and other assets remain recoverable.

Vaikutus: Potential write-downs

Stock-based compensation

Equity awards require valuation assumptions that affect operating expenses.

Vaikutus: Reported SG&A and R&D

Income tax reserves

Tax positions and reserves depend on estimates and can change with new information.

Vaikutus: Net income and balance sheet

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Nuvectis Pharma, Inc.

NVCT · Pharmaceutical Preparations

Nu-Med Plus, Inc.

NUMD · Surgical & Medical Instruments & Apparatus

Nephros, Inc

NEPH · Surgical & Medical Instruments & Apparatus

Nuvalent, Inc.

Pharmaceutical Preparations

Adagio Medical Holdings, Inc.

ADGM · Surgical & Medical Instruments & Apparatus

Teleflex Incorporated

TFX · Surgical & Medical Instruments & Apparatus

Päivitetty: 24.9.2026

Nuwellis, Inc. (NUWE) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo